Slide 1: H1 and Q2 2023 Results
H1 and Q2 2023 Results Conference call and webcast for investors and analysts 28 July 2023
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: This document contains certain forward-looking statements wit
Slide 3: Conference call agenda
H1 and Q2 2023 results Conference call agenda CEO Opening Remarks Pascal Soriot Chief Executive Officer Financial Results Aradhana Sarin Chief Financial Officer Oncology Dave Fredrickson Susan Galbraith EVP, Oncology Business EVP, Oncology R&D BioPharmaceuticals Ruud Dobber Mene Pangalos EVP, BioPha
Slide 4: CEO Opening Remarks
CEO Opening Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER
Slide 5: Benefitting from broad-based, diverse source of revenue
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Benefitting from broad-based, diverse source of revenue Strong commercial performance Broad-based, diverse source of revenue and financial execution in H1 2023 Total Revenue | +4% Core EPS | +21% H1 20
Slide 6: Strong ex-COVID-19 growth across regions, disease areas
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Strong ex-COVID-19 growth across regions, disease areas Double-digit growth across Oncology, CVRM, R&I Double-digit growth in US, Emerging Market, EU and Rare disease H1 Total Revenues (USD millions) a
Slide 7: Demand for multiple medicines driving H1 growth
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Demand for multiple medicines driving H1 growth H1 2023 Performance Total Revenue Growth vs. PY Growth vs. PY USD million USD million CER% Farxiga 2,834 729 40% Imfinzi 1,976 682 57% Ultomiris 1,364 51
Slide 8: Leading late-stage pipeline, proven R&D execution
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Leading late-stage pipeline, proven R&D execution Robust late-stage pipeline comprised of both Continued pipeline momentum with 8 positive LCM and NME opportunities pivotal trials in H1 2023 and cataly
Slide 9: Financial Results
Financial Results Aradhana Sarin CHIEF FINANCIAL OFFICER
Slide 10: H1 2023 – Reported profit and loss
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks H1 2023 – Reported profit and loss H1 2023 CER change % Total Q2 2023 CER change % Total $m % Revenue $m % Revenue Total Revenue 22,295 4 100 11,416 9 100 - Product Sales 21,448 3 96 10,882 5 95 - Alli
Slide 11: H1 2023 – Core profit and loss
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks H1 2023 – Core profit and loss H1 2023 CER change % Total Q2 2023 CER change % Total $m % Revenue $m % Revenue Total Revenue 22,295 4 100 11,416 9 100 - Product Sales 21,448 3 96 10,882 5 95 - Alliance
Slide 12: Cash Flow, Net Debt and 2023 Financial Guidance
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Cash Flow, Net Debt and 2023 Financial Guidance Continued EBITDA improvement Net Debt bridge Reiterating 2023 Guidance (CER) $bn Total Revenue • Excluding COVID-19 medicines: low double-digit % growth
Slide 13: AI in Global Operations
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks AI in Global Operations Leveraging the power of AI throughout our end-to-end supply chain GLOBAL OPERATIONS | drug development, manufacturing and supply chain powered by AI Drug development Manufacturi
Slide 14: Oncology
Oncology Dave Fredrickson ONCOLOGY BUSINESS Susan Galbraith ONCOLOGY R&D
Slide 15: Oncology – H1 and Q2 2023
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology – H1 and Q2 2023 Total Revenue +22% in H1 2023 fuelled by demand growth and launch momentum Oncology Q2 2023: key dynamics H1 2023 $8.8bn, +22% 5,000 • Tagrisso +10%, strong global demand grow
Slide 16: Oncology – key Imfinzi opportunities in focus
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology – key Imfinzi opportunities in focus Strong launch uptake, robust LCM pipeline supporting continued IO leadership Imfinzi new launches continue to LCM HLRs in 2023 contribute to drive near-ter
Slide 17: Oncology – R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology – R&D highlights Eight positive pivotal trial readouts so far this year ASCO highlights 2023 FLAURA2 | 1L EGFRm advanced NSCLC Presidential plenary WCLC Tagrisso Tagrisso ADAURA final overall
Slide 18: Oncology – R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology – R&D highlights TROPION-Lung01 reinforces importance of Dato-DXd in NSCLC and beyond Replace CTx as Further outcomes with Assess predictive value of TROPION-Lung01 monotherapy novel combinati
Slide 19: BioPharmaceuticals
BioPharmaceuticals Ruud Dobber BIOPHARMACEUTICALS BUSINESS Mene Pangalos BIOPHARMACEUTICALS R&D
Slide 20: BioPharmaceuticals – H1 and Q2 2023
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks BioPharmaceuticals – H1 and Q2 2023 Double digit growth from CVRM and R&I CVRM R&I V&I H1 2023 $5.2bn, +20% H1 2023 $3.2bn, +10% H1 2023 $632m, -76% 1,800 2,500 3,000 1,600 2,500 1,400 2,000 1,200 2,00
Slide 21: Farxiga – strategic development
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Farxiga – strategic development Redefined outcomes for patients, clear evidence of AstraZeneca’s core strength in CVRM Diverse source of Growth driven by HF and CKD1 Farxiga SGLT2i class leadership2 To
Slide 22: BioPharmaceuticals – R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks BioPharmaceuticals – R&D highlights ATS and ERA data highlights improvement in patient outcomes across R&I and CVRM tozorakimab Breztri Farxiga and Lokelma Severe viral lung infection Real-world eviden
Slide 23: BioPharmaceuticals – novel platforms
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks BioPharmaceuticals – novel platforms Disruptive biology to access next-generation therapeutics Oligonucleotides Advanced biologics Cell therapy RNA therapies Gene therapy eplontersen (TTR ASO), MEDI735
Slide 24: Rare Disease
Rare Disease Marc Dunoyer CHIEF EXECUTIVE OFFICER, ALEXION
Slide 25: Rare Disease – H1 and Q2 2023
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Rare Disease – H1 and Q2 2023 Continued expansion in neurology, growth beyond complement Rare Disease Q2 2023: key dynamics H1 2023 $3.8bn, +12% 2,500 Continued strength of C5 Franchise 2,000 • Ultomir
Slide 26: Rare Disease – R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Rare Disease – R&D highlights Accelerating in ALXN2220 to Phase III for ATTR-CM ALXN2220 (NI006) | mAb IgG1 Complimentary mechanisms Phase Ib1 in ATTR-CM transforming ATTR-CM Representative images from
Slide 27: Rare Disease – R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Rare Disease – R&D highlights Innovative delivery platforms expanding genomic research Furthering our Liver, + + + + genomic capabilities kidney gene editing sAAVyTM CRISPR non-viral ALXN2030 non-viral
Slide 28: CEO Closing Remarks
CEO Closing Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER
Slide 29: Progressing Ambition Zero Carbon
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Progressing Ambition Zero Carbon Taking bold action to mitigate climate change through new and expanded initiatives AMBITION ZERO CARBON | on track to deliver absolute reductions in GHG emissions acros
Slide 30: Robust Phase III catalysts in H2 2023
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Robust Phase III catalysts in H2 2023 Key trial readouts reinforce transformative pipeline potential capivasertib Fasenra Dato-DXd Total Revenue ambition1: CAPItello-290 MANDARA TROPION-Breast01 low do
Slide 31: BioPharmaceuticals R&D leadership change
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks BioPharmaceuticals R&D leadership change Mene Pangalos Sharon Barr to retire after almost 14 years to assume role of EVP, with AstraZeneca BioPharmaceuticals R&D 31
Slide 32: Question & Answer Session
Question & Answer Session Pascal Soriot Aradhana Sarin Marc Dunoyer E XE CUTIVE DIRE CTOR & E XE CUTIVE DIRE CTOR & CHIE F E XE CUTIVE OFFICE R, CHIE F E XE CUTIVE OFFICE R CHIE F FINANCIAL OFFICE R ALE XION Susan Galbraith Dave Fredrickson Mene Pangalos E XE CUTIVE VICE PRE SIDE NT, E XE CUTIVE VIC
Slide 33: Appendix
Appendix ▪ Pipeline Highlights ▪ Oncology tumour maps ▪ Emerging Markets performance ▪ Key medicines performance by therapy area
Slide 34: Delivering on science-led innovation
AP P E ND I X | Pipeline Highlights Delivering on science-led innovation Selected key pipeline highlights since Q1 2023 results Oncology BioPharmaceuticals Rare Disease 10 regulatory approvals in major markets, including: Lynparza (US) Farxiga (US) Soliris (EU) prostate cancer (1st-line) (PROpel) HF
Slide 35: AstraZeneca in Lung Cancer
AP P E ND I X | Oncology tumour maps AstraZeneca in Lung Cancer Ambition for >50% of lung cancer patients to be eligible for AZN medicine by 2030 metastatic resectable Stg. I-III unresectable Stg. I-II Stg. III 1L 2L+ Leading the future of Est. epi (G7) ~200K ~30K ~70K ~350K ~290K lung cancer treatm
Slide 36: AstraZeneca in Breast Cancer
AP P E ND I X | Oncology tumour maps AstraZeneca in Breast Cancer Ambition to eliminate breast cancer as a cause of death Early Metastatic established SoC Neoadjuvant Adjuvant 1st line 2nd line 3rd line 4th line + Est. epi (G7) 540k 125k 90k 65k 55k NST→ residual disease → HER2-positive Enhertu +/-
Slide 37: Emerging Markets – H1 2023
AP P E ND I X | Emerging Markets Emerging Markets – H1 2023 Total Revenue +9% at CER to $6.3bn, +22% at CER ex-COVID-19 medicines 4,000 3,500 3,000 2,500 Total Revenue ($m) 2,000 1,500 1,000 500 0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2021 2022 2023 China Emerging Markets ex-China COVID-19 medicines 37 Growth
Slide 38: Oncology – Tagrisso, Imfinzi
AP P E ND I X | H1 2023 Product Performance Oncology Tagrisso Imfinzi 12% growth at CER to $2,915m in H1 2023 57% growth at CER to $1,976m in H1 2023 1,600 1,200 1,400 1,000 1,200 Total Revenue ($m) Total Revenue ($m) 1,000 800 800 600 600 400 400 200 200 0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 0 Q2 Q3 Q4 Q1 Q
Slide 39: Oncology – Lynparza
AP P E ND I X | H1 2023 Product Performance Oncology Lynparza Lynparza 10% growth at CER to $1,368m in H1 2023 Collaboration Revenue: $3.8bn recorded cumulative, $3.9bn future potential 600 800 700 Collaboration Revenue ($m) 600 Product Sales ($m) 500 400 400 300 200 200 100 0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q
Slide 40: Oncology – Calquence, Enhertu
AP P E ND I X | H1 2023 Product Performance Oncology Calquence Enhertu 33% growth at CER to $1,185m in H1 2023 >2x growth at CER to $580m in H1 2023 700 350 600 300 500 250 Total Revenue ($m) Total Revenue ($m) 400 200 300 150 200 100 100 50 0 0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2
Slide 41: BioPharmaceuticals: Cardiovascular, Renal & Metabolism
AP P E ND I X | H1 2023 Product Performance BioPharmaceuticals: Cardiovascular, Renal & Metabolism Farxiga Brilinta Lokelma 40% growth at CER to $2,834m in H1 2023 1% growth at CER to $665m in H1 2023 59% growth at CER to $198m in H1 2023 1,600 400 120 1,400 350 100 1,200 300 Total Revenue ($m) Tota
Slide 42: BioPharmaceuticals: Respiratory & Immunology
AP P E ND I X | H1 2023 Product Performance BioPharmaceuticals: Respiratory & Immunology Fasenra Breztri Tezspire 14% growth at CER to $744m in H1 2023 76% growth at CER to $307m in H1 2023 >8x growth at CER to $135m in H1 2023 450 180 90 400 160 80 350 140 70 Total Revenue ($m) Total Revenue ($m) T
Slide 43: BioPharmaceuticals: Respiratory & Immunology
AP P E ND I X | H1 2023 Product Performance BioPharmaceuticals: Respiratory & Immunology Symbicort Pulmicort 4% growth at CER to $1,288m in H1 2023 11% growth at CER to $346m in H1 2023 800 300 700 250 600 Total Revenue ($m) Total Revenue ($m) 200 500 400 150 300 100 200 50 100 0 0 Q2 Q3 Q4 Q1 Q2 Q3
Slide 44: Rare Disease
AP P E ND I X | H1 2023 Product Performance Rare Disease Soliris Ultomiris Strensiq 16% decrease at CER to $1,648m in H1 2023 64% growth at CER to $1,364m in H1 2023 26% growth at CER to $562m in H1 2023 1,200 800 350 700 300 1,000 600 250 Total Revenue ($m) Total Revenue ($m) Total Revenue ($m) 800